Barinthus secures up to $34.8M CEPI funding for MERS vaccine VTP-500 development

Barinthus Biotherapeutics plc.

CEPI to provide $34.8M to advance VTP-500 through Phase II trials and develop 100,000-dose ready reserve.
VTP-500 received EMA PRIME designation in December 2023, supporting accelerated regulatory review.
Barinthus retains ownership of IP; will pay CEPI mid-single digit royalties on net sales and mid-double digit revenue share.
Partnership with University of Oxford builds on ChAdOx1 platform used in Oxford-AstraZeneca COVID-19 vaccine.
Equitable access commitments: LMICs receive vaccine at cost plus 10%; CEPI can support technology transfer.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Barinthus Biotherapeutics plc. entered into Funding Agreement with Coalition for Epidemic Preparedness Innovations (CEPI) and the Chancellors, Masters and Scholars of the University of Oxford valued at up to $34.8 million (effective 2023-12-20).

Action: entry
Agreement: collaboration
Counterparty: Coalition for Epidemic Preparedness Innovations (CEPI) and the Chancellors, Masters and Scholars of the University of Oxford
Value: up to $34.8 million
Effective: 2023-12-20

Exact text from the filing

On December 20, 2023, Barinthus Biotherapeutics plc (the “Company”), the Chancellors, Masters and Scholars of the University of Oxford (“Oxford,” together with the Company, the “Partners”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) entered into a Funding Agreement (the “Funding Agreement”) pursuant to which CEPI will provide funding of up to $34.8 million to the Company to advance the development of VTP-500, the Company’s vaccine candidate against Middle East Respiratory Syndrome (“MERS,” and such development activities, the “Project”).

View on SEC.gov

Browse all material agreements →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001104659-23-128782

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.